Mason Carrico
Stock Analyst at Stephens & Co.
(3.58)
# 793
Out of 5,152 analysts
77
Total ratings
45.59%
Success rate
8.66%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $197.14 | +19.20% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.52 | +31.58% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.75 | +0.33% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $9.13 | +20.48% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $34.00 | +97.06% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $128.24 | -18.12% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $21.64 | -35.30% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $18.75 | +113.33% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $112.10 | +2.59% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $34.68 | +29.76% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $92.58 | -40.59% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.38 | +36.99% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $18.57 | -8.45% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $71.36 | -27.13% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.13 | +289.86% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $27.91 | +46.90% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $197.14
Upside: +19.20%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.52
Upside: +31.58%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.75
Upside: +0.33%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $9.13
Upside: +20.48%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $34.00
Upside: +97.06%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $128.24
Upside: -18.12%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $21.64
Upside: -35.30%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $18.75
Upside: +113.33%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $112.10
Upside: +2.59%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $34.68
Upside: +29.76%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $92.58
Upside: -40.59%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.38
Upside: +36.99%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $18.57
Upside: -8.45%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $71.36
Upside: -27.13%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.13
Upside: +289.86%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $27.91
Upside: +46.90%